In NSCLC patients with EGFR mutation, disease progression in the CNS is unique to other organs since the CNS has a highly specialized neurovascular structure, the blood–brain barrier (BBB), which limits drug penetration and may serve as a sanctuary for tumor cells [2, 8]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.